Viatris Believes Eylea Biosimilar Candidate Is First To Reach US FDA’s Desk
As Viatris Discloses ‘Challenging’ Orencia Biosimilar Is Part Of Pipeline Again
Executive Summary
Viatris provided several key updates for its biosimilar pipeline during the company’s Q3 earnings call, including for its biosimilar Eylea and Botox candidates, as well as disclosing another key early-stage asset.
You may also be interested in...
Biocon Closes $3bn Deal For Viatris Biosimilars
Biocon has achieved a milestone after its Biocon Biologics subsidiary closed its $3bn deal to acquire the biosimilars business of longtime partner Viatris, in what management described as a “historic inflection point” for the Indian player.
Viatris Tipped To Knock Out Crucial Eylea Dosing Patents In US
A senior analyst for a major investment bank has listened to oral arguments in Viatris’ legal tussle vs. Regeneron over two key US dosing patents shielding the originator’s Eylea (aflibercept) blockbuster.
Alvotech Kicks Off Trials For Eylea Biosimilar
Alvotech has announced the start of clinical trials for its AVT06 proposed aflibercept biosimilar rival to Eylea, joining a host of other developers pursuing the same target.